{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T23:24:55Z","timestamp":1794007495027,"version":"4.8.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T00:00:00Z","timestamp":1729209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T00:00:00Z","timestamp":1729209600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100007132","name":"Otsuka Pharmaceutical Co., Ltd.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007132","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s40263-024-01124-w","type":"journal-article","created":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T18:02:57Z","timestamp":1729274577000},"page":"1003-1016","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["A Multicenter, Open-Label Study to Evaluate the Long-term Safety and Efficacy of Adjunctive Brexpiprazole 2 mg Daily in Japanese Patients with Major Depressive Disorder"],"prefix":"10.1007","volume":"38","clinical-trial-number":[{"clinical-trial-number":"nct03737474","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Masaki","family":"Kato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masako","family":"Shiosakai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuo","family":"Kuwahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuhiro","family":"Iba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Shimada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mizuki","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Sekine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6635-4218","authenticated-orcid":false,"given":"Kazuo","family":"Aoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Shiomi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teruhiko","family":"Higuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,18]]},"reference":[{"issue":"13","key":"1124_CR1","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/1471-244X-13-51","volume":"11","author":"I Romera","year":"2013","unstructured":"Romera I, P\u00e9rez V, Ciudad A, Caballero L, Roca M, Polavieja P, et al. Residual symptoms and functioning in depression, does the type of residual symptom matter? A post-hoc analysis. BMC Psychiatry. 2013;11(13):51.","journal-title":"BMC Psychiatry"},{"issue":"Suppl","key":"1124_CR2","first-page":"29","volume":"54","author":"DJ Kupfer","year":"1993","unstructured":"Kupfer DJ. Management of recurrent depression. J Clin Psychiatry. 1993;54(Suppl):29\u201333.","journal-title":"J Clin Psychiatry"},{"issue":"3 Suppl 1","key":"1124_CR3","first-page":"10s","volume":"49","author":"RS McIntyre","year":"2004","unstructured":"McIntyre RS, O\u2019Donovan C. The human cost of not achieving full remission in depression. Can J Psychiatry Revue canadienne de psychiatrie. 2004;49(3 Suppl 1):10s-s16.","journal-title":"Can J Psychiatry Revue canadienne de psychiatrie."},{"issue":"4","key":"1124_CR4","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1001\/jamapsychiatry.2017.4602","volume":"75","author":"DS Hasin","year":"2018","unstructured":"Hasin DS, Sarvet AL, Meyers JL, Saha TD, Ruan WJ, Stohl M, et al. Epidemiology of adult DSM-5 major depressive disorder and its specifiers in the United States. JAMA Psychiat. 2018;75(4):336\u201346.","journal-title":"JAMA Psychiat"},{"issue":"Suppl 2","key":"1124_CR5","first-page":"133","volume":"36","author":"MB Keller","year":"2002","unstructured":"Keller MB, Berndt ER. Depression treatment: a lifelong commitment? Psychopharmacol Bull. 2002;36(Suppl 2):133\u201341.","journal-title":"Psychopharmacol Bull"},{"issue":"Suppl 13","key":"1124_CR6","first-page":"14","volume":"58","author":"AJ Rush","year":"1997","unstructured":"Rush AJ, Thase ME. Strategies and tactics in the treatment of chronic depression. J Clin Psychiatry. 1997;58(Suppl 13):14\u201322.","journal-title":"J Clin Psychiatry"},{"issue":"10","key":"1124_CR7","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1001\/archpsyc.1992.01820100053010","volume":"49","author":"MB Keller","year":"1992","unstructured":"Keller MB, Lavori PW, Mueller TI, Endicott J, Coryell W, Hirschfeld RMA, et al. Time to recovery, chronicity, and levels of psychopathology in major depression: A 5-year prospective follow-up of 431 subjects. Arch Gen Psychiatry. 1992;49(10):809\u201316.","journal-title":"Arch Gen Psychiatry"},{"issue":"1","key":"1124_CR8","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/s41380-020-0843-0","volume":"26","author":"M Kato","year":"2021","unstructured":"Kato M, Hori H, Inoue T, Iga J, Iwata M, Inagaki T, et al. Discontinuation of antidepressants after remission with antidepressant medication in major depressive disorder: a systematic review and meta-analysis. Mol Psychiatry. 2021;26(1):118\u201333.","journal-title":"Mol Psychiatry"},{"issue":"14","key":"1124_CR9","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1056\/NEJMoa2106356","volume":"385","author":"G Lewis","year":"2021","unstructured":"Lewis G, Marston L, Duffy L, Freemantle N, Gilbody S, Hunter R, et al. Maintenance or discontinuation of antidepressants in primary care. N Engl J Med. 2021;385(14):1257\u201367.","journal-title":"N Engl J Med"},{"issue":"3","key":"1124_CR10","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1017\/S2045796015000566","volume":"25","author":"H Ishikawa","year":"2016","unstructured":"Ishikawa H, Kawakami N, Kessler RC. Lifetime and 12-month prevalence, severity and unmet need for treatment of common mental disorders in Japan: results from the final dataset of World Mental Health Japan Survey. Epidemiol Psychiatr Sci. 2016;25(3):217\u201329.","journal-title":"Epidemiol Psychiatr Sci"},{"key":"1124_CR11","volume":"80","author":"H Cai","year":"2023","unstructured":"Cai H, Jin Y, Liu R, Zhang Q, Su Z, Ungvari GS, et al. Global prevalence of depression in older adults: A systematic review and meta-analysis of epidemiological surveys. Asian J Psychiatr. 2023;80: 103417.","journal-title":"Asian J Psychiatr"},{"issue":"7","key":"1124_CR12","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1056\/NEJMcp2305428","volume":"390","author":"DC Steffens","year":"2024","unstructured":"Steffens DC. Treatment-resistant depression in older adults. New Engl J Med. 2024;390(7):630\u20139.","journal-title":"New Engl J Med."},{"key":"1124_CR13","unstructured":"Committee for Treatment Guidelines of Mood Disorders of the Japanese Society of Mood Disorders. Guidelines for treatment of depression. Edition 2. Tokyo: Igaku-509 shoin Ltd.; 2017."},{"issue":"11","key":"1124_CR14","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1176\/ajp.2006.163.11.1905","volume":"163","author":"AJ Rush","year":"2006","unstructured":"Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163(11):1905\u201317.","journal-title":"Am J Psychiatry"},{"issue":"4","key":"1124_CR15","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1017\/S1092852900020216","volume":"14","author":"RM Berman","year":"2009","unstructured":"Berman RM, Fava M, Thase ME, Trivedi MH, Swanink R, McQuade RD, et al. Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants. CNS Spectr. 2009;14(4):197\u2013206.","journal-title":"CNS Spectr"},{"issue":"3","key":"1124_CR16","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.jad.2013.07.035","volume":"151","author":"K Kamijima","year":"2013","unstructured":"Kamijima K, Higuchi T, Ishigooka J, Ohmori T, Ozaki N, Kanba S, et al. Aripiprazole augmentation to antidepressant therapy in Japanese patients with major depressive disorder: A randomized, double-blind, placebo-controlled study (ADMIRE study). J Affect Dis. 2013;151(3):899\u2013905.","journal-title":"J Affect Dis"},{"issue":"9","key":"1124_CR17","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1093\/ijnp\/pyaa033","volume":"23","author":"RW Taylor","year":"2020","unstructured":"Taylor RW, Marwood L, Oprea E, DeAngel V, Mather S, Valentini B, et al. Pharmacological augmentation in unipolar depression: A guide to the guidelines. Int J Neuropsychopharmacol. 2020;23(9):587\u2013625.","journal-title":"Int J Neuropsychopharmacol"},{"issue":"10","key":"1124_CR18","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1586\/14737175.2015.1086269","volume":"15","author":"L Citrome","year":"2015","unstructured":"Citrome L, Stensb\u00f8l TB, Maeda K. The preclinical profile of brexpiprazole: what is its clinical relevance for the treatment of psychiatric disorders? Expert Rev Neurother. 2015;15(10):1219\u201329.","journal-title":"Expert Rev Neurother"},{"issue":"3","key":"1124_CR19","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1124\/jpet.114.213793","volume":"350","author":"K Maeda","year":"2014","unstructured":"Maeda K, Sugino H, Akazawa H, Amada N, Shimada J, Futamura T, et al. Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulator. J Pharmacol Exp Ther. 2014;350(3):589\u2013604.","journal-title":"J Pharmacol Exp Ther"},{"key":"1124_CR20","doi-asserted-by":"crossref","unstructured":"Hobart M, Skuban A, Zhang P, Augustine C, Brewer C, Hefting N, et al. A randomized, placebo-controlled study of the efficacy and safety of fixed-dose brexpiprazole 2 mg\/d as adjunctive treatment of adults with major depressive disorder. J Clin Psychiatry. 2018;79(4), 17m12058.","DOI":"10.4088\/JCP.17m12058"},{"issue":"4","key":"1124_CR21","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1080\/03007995.2018.1430220","volume":"34","author":"M Hobart","year":"2018","unstructured":"Hobart M, Skuban A, Zhang P, Josiassen MK, Hefting N, Augustine C, et al. Efficacy and safety of flexibly dosed brexpiprazole for the adjunctive treatment of major depressive disorder: a randomized, active-referenced, placebo-controlled study. Curr Med Res Opin. 2018;34(4):633\u201342.","journal-title":"Curr Med Res Opin"},{"issue":"9","key":"1124_CR22","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.4088\/JCP.14m09688","volume":"76","author":"ME Thase","year":"2015","unstructured":"Thase ME, Youakim JM, Skuban A, Hobart M, Augustine C, Zhang P, et al. Efficacy and safety of adjunctive brexpiprazole 2 mg in major depressive disorder: a phase 3, randomized, placebo-controlled study in patients with inadequate response to antidepressants. J Clin Psychiatry. 2015;76(9):1224\u201331.","journal-title":"J Clin Psychiatry"},{"issue":"9","key":"1124_CR23","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.4088\/JCP.14m09689","volume":"76","author":"ME Thase","year":"2015","unstructured":"Thase ME, Youakim JM, Skuban A, Hobart M, Zhang P, McQuade RD, et al. Adjunctive brexpiprazole 1 and 3 mg for patients with major depressive disorder following inadequate response to antidepressants: a phase 3, randomized, double-blind study. J Clin Psychiatry. 2015;76(9):1232\u201340.","journal-title":"J Clin Psychiatry"},{"issue":"3","key":"1124_CR24","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/JCP.0000000000001034","volume":"39","author":"M Hobart","year":"2019","unstructured":"Hobart M, Zhang P, Skuban A, Brewer C, Hefting N, Sanchez R, et al. A long-term, open-label study to evaluate the safety and tolerability of brexpiprazole as adjunctive therapy in adults with major depressive disorder. J Clin Psychopharmacol. 2019;39(3):203\u20139.","journal-title":"J Clin Psychopharmacol"},{"issue":"10","key":"1124_CR25","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1002\/gps.4952","volume":"33","author":"U Lepola","year":"2018","unstructured":"Lepola U, Hefting N, Zhang D, Hobart M. Adjunctive brexpiprazole for elderly patients with major depressive disorder: An open-label, long-term safety and tolerability study. Int J Geriatr Psychiatry. 2018;33(10):1403\u201310.","journal-title":"Int J Geriatr Psychiatry"},{"issue":"1","key":"1124_CR26","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1002\/jcph.979","volume":"58","author":"J Ishigooka","year":"2018","unstructured":"Ishigooka J, Iwashita S, Higashi K, Liew EL, Tadori Y. Pharmacokinetics and safety of brexpiprazole following multiple-dose administration to Japanese patients with schizophrenia. J Clin Pharmacol. 2018;58(1):74\u201380.","journal-title":"J Clin Pharmacol"},{"key":"1124_CR27","doi-asserted-by":"publisher","DOI":"10.1111\/pcn(n\/a)","author":"M Kato","year":"2023","unstructured":"Kato M, Shiosakai M, Kuwahara K, Iba K, Shimada Y, Saito M, et al. Adjunctive brexpiprazole 1 mg and 2 mg daily for Japanese patients with major depressive disorder following inadequate response to antidepressants: a phase 2\/3, randomized, double-blind (BLESS) study. Psychiatry Clin Neurosci. 2024;78(2):113\u201322.","journal-title":"Psychiatry Clin Neurosci"},{"key":"1124_CR28","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1192\/bjp.134.4.382","volume":"134","author":"SA Montgomery","year":"1979","unstructured":"Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry J Ment Sci. 1979;134:382\u20139.","journal-title":"Br J Psychiatry J Ment Sci"},{"issue":"1","key":"1124_CR29","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1136\/jnnp.23.1.56","volume":"23","author":"M Hamilton","year":"1960","unstructured":"Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23(1):56\u201362.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1124_CR30","volume-title":"ECDEU Assessment Manual for","year":"1976","unstructured":"Guy W, editor. ECDEU Assessment Manual for. Rockville: Psychopharmacology US Department of Heath, Education, and Welfare Public Health Service Alcohol, Drug Abuse, and Mental Health Administration; 1976."},{"issue":"7","key":"1124_CR31","first-page":"28","volume":"4","author":"J Busner","year":"2007","unstructured":"Busner J, Targum SD. The clinical global impressions scale: applying a research tool in clinical practice. Psychiatry (Edgmont (Pa\u202f: Township)). 2007;4(7):28\u201337.","journal-title":"Psychiatry (Edgmont (Pa : Township))"},{"issue":"1","key":"1124_CR32","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/hup.2500","volume":"31","author":"DV Sheehan","year":"2016","unstructured":"Sheehan DV, Mancini M, Wang J, Berggren L, Cao H, Due\u00f1as HJ, et al. Assessment of functional outcomes by Sheehan Disability Scale in patients with major depressive disorder treated with duloxetine versus selective serotonin reuptake inhibitors. Hum Psychopharmacol. 2016;31(1):53\u201363.","journal-title":"Hum Psychopharmacol"},{"issue":"5","key":"1124_CR33","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1097\/YIC.0000000000000226","volume":"33","author":"C Weiss","year":"2018","unstructured":"Weiss C, Weiller E, Baker RA, Duffy RA, Gwin KK, Zhang P, et al. The effects of brexpiprazole and aripiprazole on body weight as monotherapy in patients with schizophrenia and as adjunctive treatment in patients with major depressive disorder: an analysis of short-term and long-term studies. Int Clin Psychopharmacol. 2018;33(5):255\u201360.","journal-title":"Int Clin Psychopharmacol"},{"issue":"11","key":"1124_CR34","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.4088\/JCP.v66n1118","volume":"66","author":"SW Andersen","year":"2005","unstructured":"Andersen SW, Clemow DB, Corya SA. Long-term weight gain in patients treated with open-label olanzapine in combination with fluoxetine for major depressive disorder. J Clin Psychiatry. 2005;66(11):1468\u201376.","journal-title":"J Clin Psychiatry"},{"issue":"9","key":"1124_CR35","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1111\/pcn.13438","volume":"76","author":"Y Furukawa","year":"2022","unstructured":"Furukawa Y, Oguro S, Obata S, Hamza T, Ostinelli EG, Kasai K. Optimal dose of brexpiprazole for augmentation therapy of antidepressant-refractory depression: a systematic review and dose-effect meta-analysis. Psychiatry Clin Neurosci. 2022;76(9):416\u201322.","journal-title":"Psychiatry Clin Neurosci"},{"issue":"5","key":"1124_CR36","doi-asserted-by":"crossref","first-page":"363","DOI":"10.2165\/00002512-200017050-00004","volume":"17","author":"MP Caligiuri","year":"2000","unstructured":"Caligiuri MP, Jeste DV, Lacro JP. Antipsychotic-induced movement disorders in the elderly. Drugs Aging. 2000;17(5):363\u201384.","journal-title":"Drugs Aging"},{"issue":"1","key":"1124_CR37","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1002\/npr2.12414","volume":"44","author":"T Kishi","year":"2024","unstructured":"Kishi T, Sakuma K, Saito T, Nakagawa A, Kato M, Iwata N. Comparison of brexpiprazole, aripiprazole, and placebo for Japanese major depressive disorder: a systematic review and network meta-analysis. Neuropsychopharmacology reports. 2024;44(1):165\u201375.","journal-title":"Neuropsychopharmacology reports."},{"key":"1124_CR38","doi-asserted-by":"crossref","first-page":"20r02799","DOI":"10.4088\/PCC.20r02799","volume":"23","author":"A Seshadri","year":"2021","unstructured":"Seshadri A, Wermers ME, Habermann TJ, Singh B. Long-term efficacy and tolerability of adjunctive aripiprazole for major depressive disorder: Systematic review and meta-analysis. Prim Care Companion CNS Disord. 2021;23:20r02799.","journal-title":"Prim Care Companion CNS Disord"},{"issue":"15","key":"1124_CR39","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1080\/14656566.2019.1638913","volume":"20","author":"ME Thase","year":"2019","unstructured":"Thase ME, Zhang P, Weiss C, Meehan SR, Hobart M. Efficacy and safety of brexpiprazole as adjunctive treatment in major depressive disorder: overview of four short-term studies. Expert Opin Pharmacother. 2019;20(15):1907\u201316.","journal-title":"Expert Opin Pharmacother"},{"issue":"11","key":"1124_CR40","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1093\/ijnp\/pyz040","volume":"22","author":"T Kishi","year":"2019","unstructured":"Kishi T, Sakuma K, Nomura I, Matsuda Y, Mishima K, Iwata N. Brexpiprazole as adjunctive treatment for major depressive disorder following treatment failure with at least one antidepressant in the current episode: a systematic review and meta-analysis. Int J Neuropsychopharmacol. 2019;22(11):698\u2013709.","journal-title":"Int J Neuropsychopharmacol"},{"issue":"6","key":"1124_CR41","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1097\/JCP.0000000000001297","volume":"40","author":"AH Clayton","year":"2020","unstructured":"Clayton AH, Ivkovic J, Chen D, George V, Hobart M. Effect of brexpiprazole on prolactin and sexual functioning: An analysis of short- and long-term study data in major depressive disorder. J Clin Psychopharmacol. 2020;40(6):560\u20137.","journal-title":"J Clin Psychopharmacol"},{"issue":"2","key":"1124_CR42","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1002\/npr2.12180","volume":"41","author":"T Kikuchi","year":"2021","unstructured":"Kikuchi T, Maeda K, Suzuki M, Hirose T, Futamura T, McQuade RD. Discovery research and development history of the dopamine D(2) receptor partial agonists, aripiprazole and brexpiprazole. Neuropsychopharmacology reports. 2021;41(2):134\u201343.","journal-title":"Neuropsychopharmacology reports."},{"issue":"2","key":"1124_CR43","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2165\/11538980-000000000-00000","volume":"25","author":"CU Pae","year":"2011","unstructured":"Pae CU, Forbes A, Patkar AA. Aripiprazole as adjunctive therapy for patients with major depressive disorder: overview and implications of clinical trial data. CNS Drugs. 2011;25(2):109\u201327.","journal-title":"CNS Drugs"},{"issue":"1","key":"1124_CR44","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.pharmthera.2012.09.006","volume":"137","author":"F Artigas","year":"2013","unstructured":"Artigas F. Serotonin receptors involved in antidepressant effects. Pharmacol Ther. 2013;137(1):119\u201331.","journal-title":"Pharmacol Ther"},{"key":"1124_CR45","doi-asserted-by":"crossref","first-page":"42","DOI":"10.3389\/fpsyt.2017.00042","volume":"8","author":"V Maletic","year":"2017","unstructured":"Maletic V, Eramo A, Gwin K, Offord SJ, Duffy RA. The role of norepinephrine and its \u03b1-adrenergic receptors in the pathophysiology and treatment of major depressive disorder and schizophrenia: a systematic review. Front Psychiatry. 2017;8:42.","journal-title":"Front Psychiatry."}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-024-01124-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-024-01124-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-024-01124-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T07:27:09Z","timestamp":1735889229000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-024-01124-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,18]]},"references-count":45,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["1124"],"URL":"https:\/\/doi.org\/10.1007\/s40263-024-01124-w","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,18]]},"assertion":[{"value":"4 September 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was funded by Otsuka Pharmaceutical Co., Ltd. The sponsor participated in the design and conduction of the study and in the collection, management, analysis, and interpretation of the data and funded the preparation of the manuscript. All authors, including those affiliated with the sponsor, fulfilled all authorship criteria and participated in the review and approval of the manuscript and in the decision to submit the manuscript for publication. Medical writing support was provided by Jordana Campbell, BSc, CMPP, of inScience Communications, Springer Healthcare. This medical writing assistance and the open access fee were funded by Otsuka Pharmaceutical Co., Ltd.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"M.K. reports consulting fees for this study from Otsuka Pharmaceutical Co., Ltd.; consulting fees from outside of this study from Sumitomo Pharma Co., Ltd., Shionogi & Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Lundbeck Japan K.K., and Takeda Pharmaceutical Co., Ltd.; payment or honoraria for lectures, presentations, speakers\u2019 bureaus, manuscript writing, or educational events from Sumitomo Pharma Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Meiji Seika Pharma Co., Ltd., Eli Lilly Japan K.K., MSD K.K., Pfizer Japan Inc., Janssen Pharmaceutical K.K., Shionogi & Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Takeda Pharmaceutical Co., Ltd., Lundbeck Japan K.K., Viatris Inc., Eisai Co., Ltd., Kyowa Pharmaceutical Industry Co., Ltd., and Ono Pharmaceutical Co., Ltd. M.S., K.K., K.I., Y.S., M.S., D.S., K.A., and Y.S. are full-time employees of Otsuka Pharmaceutical Co., Ltd. T.H. reports consulting fees for this study and honoraria for lectures from Otsuka Pharmaceutical Co., Ltd.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Anonymized individual participant data that underlie the results of this study will be shared with researchers to achieve aims prespecified in a methodologically sound research proposal.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"The study protocol, protocol amendment(s), and all study-related documents were reviewed and approved by the local or central institutional review board (IRB) at each participating institution. The study was conducted in accordance with the protocol, and complied with Good Clinical Practice (GCP) guidelines, Declaration of Helsinki, and all local laws.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"All patients provided written informed consent to participate in the study.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Study concept and design: M. Kato, M. Shiosakai, K. Kuwahara, K. Iba, Y. Shimada, M. Saito, and T. Higuchi. Acquisition of data: M. Kato, M. Shiosakai, K. Kuwahara, K. Iba, Y. Shimada, M. Saito, and T. Higuchi. Analysis and interpretation of data, drafting of the manuscript, revision of it for intellectual content, and final approval of the completed manuscript: All authors. Read and approved the final submitted manuscript and agree to be accountable for the work: All authors.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship Contributions"}}]}}